LPAL2, lipoprotein(a) like 2, pseudogene, 80350

N. diseases: 53; N. variants: 12
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3536715
Disease: AA amyloidosis
AA amyloidosis 		0.010 Biomarker disease BEFREE Herein, we employed apolipoprotein A-II (ApoA-II) deficient (Apoa2 <sup>-/-</sup> ) and transgenic (Apoa2Tg) mice to investigate the potential roles of ApoA-II in lipoprotein particle formation and progression of AA amyloidosis during APR. 29618729 2018
CUI: C0268406
Disease: Age-related amyloidosis
Age-related amyloidosis 		0.010 AlteredExpression disease BEFREE An inherited polymorphism occurring in the murine apolipoprotein A-II (ApoA-II) transcript seems to be related to the senile amyloidosis which occurs in accelerated-senescence-prone mice (SAM-P). 2514123 1989
CUI: C2607914
Disease: Allergic rhinitis (disorder)
Allergic rhinitis (disorder) 		0.010 AlteredExpression disease BEFREE Mass spectrometry and biochemical analyses showed reduced levels of apoA-I and phosphatidylcholine, but increased levels of apoA-II, triglycerides and lyso-phosphatidylcholine in AR-HDL. 31185305 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.020 Biomarker disease BEFREE In contrast to apoE, no apoA-II immunoreactivity was observed with pathological structures in Alzheimer's disease brain. 9831633 1998
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.020 Biomarker disease BEFREE Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. 31524156 2019
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 Biomarker disease BEFREE The mechanisms of amyloid formation in human apoA-II amyloidosis are not clear. 11703582 2001
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 Biomarker disease BEFREE Irrespective of diet, RAGE<sup>-/-</sup> mice were significantly protected against nephrosclerosis lesions (hyalinosis, tubular atrophy, fibrosis and glomerular sclerosis) and renal senile apolipoprotein A-II (ApoA-II) amyloidosis (p < 0.001). 30794349 2019
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 Biomarker disease BEFREE In particular, all major proteins of high-density lipoproteins (HDL), including apoA-I, apoA-II and serum amyloid A, can cause systemic amyloidoses in humans upon protein mutations, post-translational modifications or overproduction. 27768903 2017
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 GeneticVariation disease BEFREE Several reports have added to our understanding of the relationship between apoA-II mutations and amyloidosis both in humans and mice. 15166779 2004
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 Biomarker disease BEFREE Our observations uncovered the critical roles of ApoA-II in inflammation, serum lipoprotein stability and AA amyloidosis morbidity, and prompt consideration of therapies for AA and other amyloidoses, whose precursor proteins are associated with circulating HDL particles. 29618729 2018
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.060 Biomarker disease BEFREE However, mouse senile apolipoprotein A-II amyloidosis (AApoAII) was detected, particularly in the joints of mice that were injected with AApoAII amyloid fibrils. 20462363 2010
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE The increased concentration of apoB-containing lipoproteins present in apoA-II transgenic mice explains, in part, why these animals present increased atherosclerosis susceptibility. 11714842 2001
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis. 30500605 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE However, there was no difference in the area of atherosclerosis of transgenic and control mice when fed a regular chow diet This contrasts with the findings in murine apoA-II transgenic mice and provides evidence of a species-specific characteristic that could be of relevance with respect to the high fat intake diets common in most industrialized countries. 9580110 1998
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 AlteredExpression disease BEFREE Studies with mice have revealed that increased expression of apolipoprotein A-II (apoA-II) results in elevations in high density lipoprotein (HDL), the formation of larger HDL, and the development of early atherosclerosis. 11290828 2001
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE Apolipoprotein A-II, HDL metabolism and atherosclerosis. 12119188 2002
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. 23241412 2013
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE Current research with transgenic mice, however, indicates that apolipoprotein A-II must be taken into consideration in understanding the development of atherosclerosis, because it appears to be a potent antagonist for the protective properties of apolipoprotein A-I. 7858910 1994
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE A strong inverse relationship exists between total plasma HDL concentration and atherosclerosis, but the results of studies examining the relationship between AI-HDL and AI/AII-HDL and atherosclerosis have been conflicting. 8413656 1993
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis. 17446329 2007
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.100 Biomarker disease BEFREE Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. 11073852 2000
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.100 Biomarker disease BEFREE Current research with transgenic mice, however, indicates that apolipoprotein A-II must be taken into consideration in understanding the development of atherosclerosis, because it appears to be a potent antagonist for the protective properties of apolipoprotein A-I. 7858910 1994
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.100 Biomarker disease BEFREE Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis. 17446329 2007
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.100 AlteredExpression disease BEFREE Studies with mice have revealed that increased expression of apolipoprotein A-II (apoA-II) results in elevations in high density lipoprotein (HDL), the formation of larger HDL, and the development of early atherosclerosis. 11290828 2001
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.100 Biomarker disease BEFREE Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. 23241412 2013